A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis

Trial ID or NCT#

NCT04308681

Status

recruiting iconRECRUITING

Purpose

The purpose of this study is to provide an initial evaluation of the effectiveness of BMS-986278 in participants with lung fibrosis, to demonstrate the safety of BMS-986278, and provide information on the drug levels of BMS-986278 in these participants.

Official Title

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants With Pulmonary Fibrosis

Eligibility Criteria

Ages Eligible for Study: Older than 21 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. For the idiopathic pulmonary fibrosis (IPF) Cohort - Diagnosis of IPF within 7 years of screening - Female and males ≥ 40 years of age For the progressive fibrotic interstitial lung disease (PF-ILD) Cohort - Evidence of progressive ILD within the 24 months before screening - Female and male ≥ 21 years of age.
Exclusion Criteria:
  1. - Women of childbearing potential (WOCBP) - Active Smokers - Current malignancy or previous malignancy up to 5 years prior to screening - History of allergy to BMS-986278 or related compounds Other protocol-defined inclusion/exclusion criteria apply
View All Criteria
Show Less

Investigator(s)

Rishi Raj
Rishi Raj
Pulmonologist
Clinical Professor, Medicine - Pulmonary, Allergy & Critical Care Medicine

Contact us to find out if this trial is right for you.

Contact

Rishi Raj, Site 0043
650-736-8083

View on ClinicalTrials.gov